Diatom Glyco-Engineering for New Therapeutical Applications – DAGENTA
Monoclonal antibodies (mAb) used to treat cancers, immune and infectious diseases represent a multibillion dollar industry. Chinese Hamster Ovary cells are currently the gold standard. However, high expense, potential virus contamination and mAb heterogeneity represent major drawbacks that drive scientists to seek alternatives. Among these, the diatom P. tricornutum represent an option because of (i) its robustness in industrial process, (ii) its ability to be cultivated in mixotrophy, (iii) its genome availability and possibility to be genetically engineered. The proof of concept in P. tricornutum has already been exemplified through the production of a glycosylated mAb. A human-like N-glycosylation is now required for mAb optimal safety and efficacy when used in human therapies. Therefore, we propose to engineer the N-glycosylation pathway of P. tricornutum by gene silencing and expressing heterologous enzymes, thus allowing galactosylated algae-made mAb production.
Madame Muriel BARDOR (GLYCOBIOLOGIE ET MATRICE EXTRACELLULAIRE VEGETALE)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
UGSF UMR 8576 - Unité de glycobiologie structurale et fonctionnelle
TWB Toulouse White Biotechnology
e-Zyvec / R et D
GlycoMEV GLYCOBIOLOGIE ET MATRICE EXTRACELLULAIRE VEGETALE
Help of the ANR 617,838 euros
Beginning and duration of the scientific project: January 2022 - 48 Months